Anti-LPAR3 (extracellular)

Antibodies

Lysophosphatidic acid receptor 3, LPA receptor 3, LPA-3, snGPCR32

Shipped at room temperature. Product as supplied can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C

Lyophilized powder. Reconstituted antibody contains phosphate buffered saline (PBS), pH 7.4

Lysophosphatidic acid receptor 3, LPA receptor 3, LPA-3, snGPCR32 - A Rabbit Polyclonal Antibody to LPA Receptor 3 (EDG7)

Mouse - identical; human - 12/14 amino acid residues identical

Confirmed by amino acid analysis and mass spectrometry

0.8 mg/ml

Extracellular, N-terminus

Rat

41116161

Lysophosphatidic acid (LPA) is a bioactive lipid molecule with a phosphate, a glycerol, and a fatty acid in its structure. The cellular effects of LPA include proliferation, migration, cytokine secretion, and morphological change. These pleiotropic actions allow LPA to participate in a wide variety of biological processes, such as brain development, oncogenesis, wound healing and cancer progression1. To date, at least 6 subtypes of LPA receptors have been identified. The LPA1-3 receptors are members of the endothelial cell differentiation gene (Edg) family2. All six receptors are type I, rhodopsin-like G-protein coupled receptors (GPCRs) that differ in their tissue distribution and downstream signaling pathways3.GPCRs share a similar topology, with seven transmembrane helices (TMHs) connected by three extracellular loops (ECLs), and three intracellular loops (ICLs); the N-terminus is on the extracellular side of the membrane, and the C-terminus is on the cytoplasmic side4.Expression of LPA3 receptor has been observed in human heart, testis, prostate, pancreas, lung, ovary, and brain5 and is most abundant in mouse testis, kidney, lung, small intestine, heart, stomach, spleen, brain, and thymus6.LPA3 receptor null mice are viable and grossly normal, but female nulls show a striking phenotype in the reproductive system7. However, despite the fact that LPA3 is expressed in the frontal cortex, hippocampus, and amygdala, no phenotypes related to LPA3 loss in the nervous system have been reported to date5.